Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024
- None.
- None.
The enrollment of the first subject in Windtree Therapeutics' phase 2 SEISMiC Extension Study for istaroxime treatment in early cardiogenic shock represents a critical juncture in the drug development pipeline. Given the high mortality rate associated with cardiogenic shock and the expressed need for innovative treatments by clinical cardiologists, the implications of this study are significant for both patient care outcomes and potential market opportunities.
Windtree's strategic move to extend the dosing duration and explore dose optimization underscores a commitment to enhancing the drug's efficacy and safety profile, which could distinguish istaroxime from existing treatments. The anticipation of topline results by mid-2024 offers a timeline for investors to monitor progress and assess potential impacts on Windtree's stock valuation.
Furthermore, the drug's dual-action mechanism and positive results from earlier trials suggest a competitive advantage in the cardiogenic shock treatment landscape. However, it is crucial to remain cognizant of the inherent risks and uncertainties in drug development, including potential regulatory challenges and the outcome of future clinical trials.
Windtree Therapeutics' advancement into the SEISMiC Extension Study for istaroxime is a notable development in the healthcare sector, particularly within the cardiology specialty. The drug's potential to address the unmet need in early cardiogenic shock treatment could lead to a significant shift in clinical practice, as indicated by the positive reception from cardiologists in market research.
Investor interest may be heightened by the fact that istaroxime targets a condition with high mortality and morbidity, where successful intervention can lead to substantial improvements in patient outcomes and healthcare costs. The study's focus on SERCA2a activation offers a novel approach that could contribute to the drug's unique positioning in the market.
While the study's outcome could have profound implications for Windtree's business trajectory and the broader cardiology treatment market, stakeholders must weigh these prospects against the rigorous demands of regulatory approval and the complexities of market penetration.
The initiation of the SEISMiC Extension Study by Windtree Therapeutics marks a pivotal phase in clinical research for istaroxime, particularly due to the drug's innovative approach to treating cardiogenic shock. The study's design, focusing on dose optimization and extended infusion times, reflects a meticulous approach to establishing a robust data set for regulatory discussions and potential phase 3 trial planning.
Positive outcomes from this trial could expedite the drug's development timeline and enhance its clinical and regulatory standing. Conversely, any setbacks or negative results could significantly delay progress and impact investor confidence. The careful monitoring of this study's progression is essential for stakeholders to evaluate both the clinical and commercial potential of istaroxime.
WARRINGTON, PA / ACCESSWIRE / December 19, 2023 / Windtree Therapeutics, Inc. (NASDAQ:WINT) has recently enrolled the first subject in its phase 2 SEISMiC Extension Study to evaluate istaroxime in the treatment of early cardiogenic shock. The phase 2 trial builds upon the positive data from the SEISMiC study in early cardiogenic shock and will add data to facilitate the company's end-of-phase 2 meeting with the FDA and is expected to lay the groundwork for choosing an optimal dose for a phase 3 trial, subject to FDA approval.
Cardiogenic Shock Requires Urgent Medical Treatment and Has Significant Unmet Need for Drug Treatment
Cardiogenic shock is characterized by low blood pressure and inadequate blood flow to vital organs and is accompanied by congestion and high filling pressures of the heart.
Mortality of cardiogenic shock is estimated to be up to
There is a significant unmet need with current drugs available and a reported desire for drug innovation. Market research was conducted with 100 U.S.-based clinical cardiologists who treat cardiogenic shock as part of their responsibility. 99 out of 100 of cardiologists indicated that drug innovation was highly needed for early cardiogenic shock. Additionally, when shown a blinded profile of istaroxime,
Istaroxime Has Already Shown Positive Results In An Early Cardiogenic Shock Trial
Istaroxime would be a first-in-class dual-action treatment that can increase blood pressure and improve heart function.
As for its ability to treat cardiogenic shock, in a recent phase 2 trial conducted by Windtree in early cardiogenic shock, the systolic blood pressure area under the curve was statistically significantly improved over the control group during the six-hour primary endpoint of the study. Systolic blood pressure was measured additionally for 24 hours and maintained statistical significance over the control group during that period of time. The study also found that istaroxime patients showed improvements in overall cardiac function. Istaroxime also had a favorable profile related to arrhythmias and kidney function (two potential points of differentiation for istaroxime versus currently used medicines).
The SEISMiC Extension Study Could Pave The Way For Phase 3
The SEISMiC Extension Study is a dose optimization study meant to find the optimal dosage of istaroxime to use if and when it moves into a phase 3 program, which remains subject to the FDA's approval. This is an important step to phase 3 readiness and will provide data to Windtree for its end-of-phase 2 meeting with the FDA.
The new phase 2 Extension is expected to enroll up to 30 hospitalized patients with early cardiogenic shock (SCAI Stage B) due to acute heart failure and will evaluate two dose regimens of istaroxime compared to placebo. Subjects on istaroxime will receive infusions for up to 60 hours with one istaroxime group receiving a tapered decreasing dose over time and the second istaroxime group receiving a consistent lower dose. In the previous SEISMiC study in early cardiogenic shock, patients were infused drug or placebo for 24 hours. The company believes extending the dosing duration of istaroxime has the potential to provide additional benefit and, along with dose titration, is an important factor in determining the optimal dosing regimen to study in a potential Phase 3 trial. The Extension Study will also gather data to characterize the potential benefits of SERCA2a activation in these patients, advancing the Company's clinical and regulatory position for potential Phase 3 readiness.
Topline results of the SEISMiC Extension Study are expected in mid-2024. The company is also progressing the start-up of a parallel study in the more severe SCAI Stage C patients targeting data in a similar timeframe.
Featured photo by Ali Hajiluyi on Unsplash.
Contact:
Matt Epstein
mepstein@kendallir.com
SOURCE: Windtree
View the original press release on accesswire.com
FAQ
What is the latest study conducted by Windtree Therapeutics, Inc. (NASDAQ:WINT)?
What is the purpose of the SEISMiC Extension Study?
What is the potential of istaroxime for treating cardiogenic shock?
When are the topline results of the SEISMiC Extension Study expected?
